Screener
Dyne Therapeutics, Inc. DYN Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.
The source filing: Dyne Therapeutics, Inc.’s 10-K, filed March 2, 2026.
- Filed
- Mar 2, 2026, 7:20 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-084178
| (in thousands) | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Proceeds from issuance of common stock in public offering, net of issuance costs | 593,957 | 675,180 | — |
| Proceeds from issuance of common stock in at-the-market offering, net of issuance costs | 140,653 | 97,871 | 52,369 |
| Proceeds from exercise of stock options | 7,999 | 36,844 | 1,953 |
| Proceeds from issuance of long-term debt, net of issuance costs paid | 148,256 | — | — |
| Payment of debt issuance costs | (558) | — | — |
| Net cash provided by financing activities | 890,307 | 809,895 | 54,322 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 458,349 | 313,450 | (50,525) |
| Cash, cash equivalents and restricted cash, beginning of year | 437,391 | 123,941 | 174,466 |
Item 16. Form 10-K Summary
FAQ
- What is Dyne Therapeutics, Inc.'s debt issuance proceeds?
- Dyne Therapeutics, Inc. (DYN) reported debt issuance proceeds of $49.45M in Q4 2025.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Dyne Therapeutics, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude